Remission of relapsed/refractory classical Hodgkin lymphoma induced by brentuximab vedotin and pembrolizumab combination after allogeneic hematopoietic stem cell transplantation: a case report

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programmed cell death protein-1 (PD-1) blocking agents hav...

Полное описание

Библиографические подробности

Главные авторы:	Federica Giannotti, Carmen De Ramon Ortiz, Federico Simonetta, Sarah Morin, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Anne-Claire Mamez
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Frontiers Media S.A. 2024-03-01
Серии:	Frontiers in Immunology
Предметы:	Hodgkin lymphoma pembrolizumab brentuximab-vedotin haploidentical allogeneic stem cell transplant DLI
Online-ссылка:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1360275/full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!